Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value
Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration to Discover Novel Immuno-Oncology Antibodies
Neurovive Pharmaceutical: NeuroVive refocuses CicloMulsion development – discontinues acute myocardial infarction indication
FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
Sanofi is lending its weight to Google's ambitions in life sciences, joining the tech giant's recently unleashed healthcare division in hopes of developing new technologies to help manage diabetes.
The FDA granted Intercept's obeticholic acid (OCA) application for primary biliary cirrhosis a priority review, setting the PDUFA date at February 29, 2016.